CoChat

Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement

Open access
Bartlett, Stephen T., Markmann, James F., Johnson, Paul, Korsgren, Olle, Hering, Bernhard J., Scharp, David, Kay, Thomas W. H., Bromberg, Jonathan, Odorico, Jon S., Weir, Gordon C., Bridges, Nancy, Kandaswamy, Raja, Stock, Peter, Friend, Peter, Gotoh, Mitsukazu, Cooper, David K. C., Park, Chung-Gyu, O'Connell, Phillip, Stabler, Cherie, Matsumoto, Shinichi, Ludwig, Barbara, Choudhary, Pratik, Kovatchev, Boris, Rickels, Michael R., Sykes, Megan, Wood, Kathryn, Kraemer, Kristy, Hwa, Albert, Stanley, Edward, Ricordi, Camillo, Zimmerman, Mark, Greenstein, Julia, Montanya, Eduard, Otonkoski, Timo · 2016 · Transplantation
Cited by 75

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Abstract

At the time the first pancreas transplant was performed by Kelly and Lillehei in 1966, insulin therapy for diabetes was generally available but administered in a form that is known today as “conventional therapy.”1 In this era, as many as half of all juvenile onset diabetics did not reach the age of 55 years. Early mortality from accelerated cardiovascular disease, renal failure, and hypoglycemia-related events were commonplace. The early low success rate and mortality of pancreas transplantation by comparison were also suboptimal. As will be characterized in the succeeding 8 chapters, the outcome of “best medical therapy” with newer forms of insulin and insulin delivery systems along with dramatically improved outcomes of islet and pancreas transplantation and novel β-cell sources hold great promise for those afflicted. Among the great strides in diabetes research was the Diabetes Control and Complications Trial (DCCT).2 This trial, published in 1991, showed that intensive insulin therapy when compared with “conventional therapy” dramatically reduced the incidence and progression of the microvascular complications of diabetes, nephropathy, neuropathy, and retinopathy. Thus, with intensive insulin therapy, the mean hemoglobin A1C was improved to 7% compared with 8.3% in the conventional group. The improved microvascular outcomes and measured hemoglobin A1C came at a substantial price, namely, a greatly increased incidence of hypoglycemic events requiring third-party intervention. After 2 decades, the 2 groups have also diverged with respect to mortality; recent reanalysis of the original study groups demonstrates that those individuals who received intensive insulin therapy groups had lower overall mortality.3 Current best practice includes the availability of insulin pumps and newer forms of synthetic insulin as well as pharmaceutical agents that augment insulin action. Unfortunately, the widespread application of the therapeutic measures taken in the intensive therapy arm of the DCCT is not the norm. Analysis of data from the 67 centers reporting to the US type 1 diabetes (T1D) exchange shows that even today, more than 20 years after the DCCT, the average hemoglobin A1C for treated patients is 8.3%. Thus, outside of a clinical trial, such as the DCCT, actual practice achieves suboptimal outcomes. A remarkable report of the current state of diabetes care is published in the Journal of the American Medical Association in January 2015. This report shows that in a modern era of diabetes care, mortality remains higher than the general population. For men and women, the life expectancy for those reaching 20 years of age is 11.1 years and 12.9 years less than the general population, respectively.4 These sobering findings, which have been thoughtfully summarized in an accompanying editorial by Katz, provide a meaningful context for an international conference dedicated to summarize the current state of pancreas and islet transplantation and chart the way forward with an ambitious research agenda.5 The need for a cure for diabetes through transplantation, stem cell–based therapy, regeneration, newer insulin delivery systems, and devices that warn of hypoglycemia have been brought into sharp focus by these reports which show that the progress in care for diabetics has hit a plateau. Innovation will be required to improve the quality of life and lower morbidity and mortality for those with insulin-requiring diabetes. Against this backdrop, the International Pancreas and Islet Transplant Association (IPITA), in collaboration with the Transplantation Society (TTS), held a scientific workshop in Oxford England, May 7 to 9, 2014, to review the current status and needed research agenda of 8 current or nascent β-cell replacement therapies: whole organ pancreas transplantation, isolated islet transplantation, artificial pancreas (AP), immunological tolerance, xenotransplantation, encapsulation technologies, β cell regeneration, and stem cell derived β cells. Thirty-two scientists and clinicians representing 4 continents, 7 countries and 29 institutions, with dedicated expertise in these areas were recruited to participate in 8 topical workgroups along with representatives of the NIH (National Institute of Diabetes and Digestive and Kidney Disease, National Institute of Allergy and Infectious Disease), Diabetes Research and Wellness Foundation, the Juvenile Diabetes Research Foundation (JDRF) and industry. In advance of the meeting, the workgroups prepared summaries of their respective topic highlighting the state of their field and the research agenda needed to move the therapy forward to optimal clinical application. Presentation and full group discussion at the meeting generated revised summaries presented in the 8 sections below. These reports are followed by the results of a conference attendee survey examining how the participants view the future of β cell replacement therapies. ALLOGENEIC PANCREAS TRANSPLANTATION Cur

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/tp.0000000000001055

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Cited by

See all 75

Metadata

Authors
Bartlett, S. T., Markmann, J. F., Johnson, P., Korsgren, O., Hering, B. J., Scharp, D., Kay, T. W. H., Bromberg, J., Odorico, J. S., Weir, G. C., Bridges, N., Kandaswamy, R., Stock, P., Friend, P., Gotoh, M., Cooper, D. K. C., Park, C.-G., O'Connell, P., Stabler, C., Matsumoto, S., Ludwig, B., Choudhary, P., Kovatchev, B., Rickels, M. R., Sykes, M., Wood, K., Kraemer, K., Hwa, A., Stanley, E., Ricordi, C., Zimmerman, M., Greenstein, J., Montanya, E., & Otonkoski, T.
Venue
Transplantation
Published
2016-02
Volume
100
Issue
Supplement 2s
Pages
S1-S44
ISSN
0041-1337 (ISSN-L)
OpenAlex
W2331130551
Cited by
75
References
62
FWCI
17.59
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement. https://app.cochat.ai/papers/10.1097/tp.0000000000001055
The paper
Bartlett, S. T., Markmann, J. F., Johnson, P., Korsgren, O., Hering, B. J., Scharp, D., Kay, T. W. H., Bromberg, J., Odorico, J. S., Weir, G. C., Bridges, N., Kandaswamy, R., Stock, P., Friend, P., Gotoh, M., Cooper, D. K. C., Park, C.-G., O'Connell, P., Stabler, C., . . . Otonkoski, T. (2016). Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement. Transplantation. https://doi.org/10.1097/tp.0000000000001055

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.